Physician profile
John L Howard
NPI 1851388235
$4,699.68
in general payments reported to CMS, 2019-2025
35 companies · $604 in 2025
The $604 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,150 · 2020: $389 · 2021: $276 · 2022: $943 · 2023: $322 · 2024: $1,014 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,940.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $843.37 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $626.68 | 2019-2025 | Dupixent |
| Optinose US, INC. | $536.74 | 2019-2025 | |
| Stryker Corporation | $402.67 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $281.03 | 2022 | |
| Glaxosmithkline, LLC. | $230.54 | 2021-2025 | Nucala |
| Acclarent, INC | $193.83 | 2019-2020 | |
| Intersect Ent, INC. | $168.18 | 2020-2021 | |
| Medtronic, INC. | $155.37 | 2022-2024 | Nuvent |
| Genzyme Corporation | $133.18 | 2022-2025 | |
| Genentech USA, INC. | $123.34 | 2019-2024 | Xolair |
| Depuy Synthes Sales INC. | $111.50 | 2019 | |
| Shire North American Group INC | $102.01 | 2019 | |
| Novartis Pharmaceuticals Corporation | $66.17 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $60.05 | 2024-2025 | Voquezna |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $59.16 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $56.96 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.90 | 2020-2025 | Takhzyro |
| Jazz Pharmaceuticals INC. | $56.23 | 2019-2020 | |
| Lundbeck LLC | $52.90 | 2023-2024 | Vyepti |
| Biocryst US Sales Co., LLC | $48.01 | 2022-2023 | Orladeyo |
| Resmed Corp | $43.50 | 2019-2020 | |
| Kaleo, INC. | $41.37 | 2019 | |
| Lilly USA, LLC | $39.85 | 2023-2025 | Ebglyss, Olumiant |
| Bioprotect Medical, INC. | $29.92 | 2025 | Bioprotect Balloon Implant System |
| Abbvie INC. | $24.09 | 2025 | |
| Philips North America LLC | $19.40 | 2019 | |
| Supernus Pharmaceuticals, INC. | $19.28 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $19.23 | 2025 | Tezspire |
| Amgen INC. | $19.00 | 2022 | |
| Hikma Pharmaceuticals USA | $18.82 | 2022 | |
| Alk-Abello, INC | $18.79 | 2019 | |
| Inspire Medical Systems, INC. | $14.96 | 2024 | Inspire |
| Karl Storz Endoscopy-America | $13.93 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.